Mutant IDH1 inhibits PI3K/Akt signaling in human glioma

Cancer

Volumn 120, Issue 16, 2014, Pages 2440-2447

  Birner, Peter ^a,b   Pusch, Stefan ^a,c   Christov, Christo ^d   Mihaylova, Stiliana ^d   Toumangelova Uzeir, Kalina ^d   Natchev, Sevdalin ^d   Schoppmann, Sebastian F ^b   Tchorbanov, Andrey ^e   Streubel, Berthold ^f   Tuettenberg, Jochen ^g   Guentchev, Marin ^g  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL ST IVAN RILSKI   (Bulgaria)

^e INSTITUTE OF MICROBIOLOGY   (Bulgaria)

^f UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^g Klinikum Idar Oberstein   (Germany)

Author keywords

Akt; astrocytoma; glioblastoma; glioma; IDH1; PDPN

Indexed keywords

2 HYDROXYGLUTARIC ACID; ISOCITRATE DEHYDROGENASE 1; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PODOPLANIN; PROTEIN KINASE B; ALCOHOL DEHYDROGENASE; D2HGDH PROTEIN, HUMAN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; MEMBRANE PROTEIN; PDPN PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER PROGNOSIS; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; GLIOSARCOMA; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL RATE; BIOSYNTHESIS; COHORT ANALYSIS; DISEASE COURSE; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PHOSPHORYLATION; TISSUE MICROARRAY; TUMOR CELL LINE;

ALCOHOL OXIDOREDUCTASES; CELL LINE, TUMOR; COHORT STUDIES; DISEASE PROGRESSION; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS;

EID: 84905668196     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28732     Document Type: Article

References (31)

1. Yan H, Parsons DW, Jin GL, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765-773.
2. Bralten LB, Kloosterhof NK, Balvers R, et al. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol. 2011; 69: 455-463.
3. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012; 483: 474-U130.
4. Engelman JA,. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Rev Cancer. 2009; 9: 550-562.
5. Cheng CK, Fan QW, Weiss WA,. PI3K Signaling in glioma-animal models and therapeutic challenges. Brain Pathol. 2009; 19: 112-120.
6. Koul D,. PTEN signaling pathways in glioblastoma. Cancer Biol Ther. 2008; 7: 1321-1325.
7. Bleau AM, Hambardzumyan D, Ozawa T, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009; 4: 226-235.
8. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17: 510-522.
9. Peterziel H, Müller J, Danner A, et al. Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation. Neuro Oncol. 2012; 14: 426-439.
10. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G,. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 2006; 9: 261-272.
11. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M,. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. 2006; 111: 483-488.
12. Colman H, Zhang L, Sulman EP, et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol. 2010; 12: 49-57.
13. Motomura K, Natsume A, Watanabe R, et al. Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. Cancer Sci. 2012; 103: 1871-1879.
14. Ernst A, Hofmann S, Ahmadi R, et al. Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res. 2009; 15: 6541-6550.
15. Ernst A, Hofmann S, Ahmadi R, et al. Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res. 2009; 15: 6541-6550.
16. Grau S, Trillsch F, Tonn JC, et al. Podoplanin contributes to migration and angiogenesis in malignant glioma in vivo. 2010. In: 62nd Annual Meeting of the German Society of Neurosurgery (DGNC); May 7-11, 2011; Hamburg, Germany; www.egms.de/static/en/meetings/dgnc2011/11dgnc248.shtml. Published April 28, 2011.
17. Madhavan S, Zenklusen JC, Kotliarov Y, Sahni H, Fine HA, Buetow K,. Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res. 2009; 7: 157-167.
18. Balss J, Pusch S, Beck AC, et al. Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate. Acta Neuropathol. 2012; 124: 883-891.
19. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A,. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009; 118: 599-601.
20. Bender R, Lange S,. Adjusting for multiple testing-when and how? J Clin Epidemiol. 2001; 54: 343-349.
21. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009; 118: 469-474.
22. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321: 1807-1812.
23. Huse JT, Brennan C, Hambardzumyan D, et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev. 2009; 23: 1327-1337.
24. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361: 1058-1066.
25. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011; 224: 334-343.
26. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012; 17: 72-79.
27. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462: 739-U52.
28. Zhao SM, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1 alpha. Science. 2009; 324: 261-265.
29. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant idh1 delays growth and promotes differentiation of glioma cells. Science. 2013; 340: 626-630.
30. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012; 483: 479-483.
31. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO,. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res. 2001; 61: 6674-6678.